About us

Scientific Team



Chris Pickford PhD, Head of Drug Discovery

Chris is currently the Head of Drug Discovery at Centauri Therapeutics. He leads the scientific team to deliver drug candidates into the clinic, responsible for the pre-clinical labs at Discovery Park, Sandwich, UK. Before joining Centauri Therapeutics, Chris was a Research Director at Agalimmune, an immuno-oncology biotech and a project leader for Salvensis, a neglected diseases drug discovery company. In addition Chris worked for 12 years as part of Pfizer’s Research and Development organization, leading infectious diseases projects from new target identification to first-in-human trials. Chris studied for a biochemistry degree at the University of Birmingham and obtained a PhD from the National Institute of Medical Research, London.



E LeireEmma Leire PhD 

Emma Leire is the Lead microbiologist at Centauri Therapeutics responsible for the in vitro and in vivo microbiology. Emma completed a joint PhD from University of Nottingham, UK and University of Santiago de Compostela, Spain in nanomedicine through an Erasmus Mundus Fellowship. Her thesis work included synthesis of novel dendritic scaffolds for antibacterial applications, studying the impact of dendrimer generations on anti-adhesion, quorum sensing and membrane permeability. Emma has been a visiting scholar at the University of California, San Diego (UCSD) studying the impact of innate immunity on pathogenesis, and has worked as a researcher at diagnostic company LifeAssays, Sweden, developing tests for inflammatory biomarkers. She earned a BSc in Molecular Biology from University of Lund, Sweden and a MSc in Pharmaceutical Sciences from University of Copenhagen, Denmark.


 Mel Glossop 2Mel Glossop BSc (Hons), MRSC, CCHem

Mel Glossop has over 20 years’ experience in both Pharmaceutical R&D and Biotechnology environments. As a project synthetic leader for Pfizer Mel led multiple global chemistry teams, both in-house and externally to enable delivery of molecules from hit-to-lead through to candidate molecule scale up to support Phase 1.  Mel has contributed to the success of multiple drug candidates for the Pfizer pain portfolio and has extensive experience of working within multidisciplinary teams to deliver all aspects of chemistry. Mel graduated from the University of Southampton, is a chartered chemist from the RSC and is author and inventor on multiple patents and publications.